申请人:Ribozyme Pharmaceuticals, Inc.
公开号:US06248878B1
公开(公告)日:2001-06-19
Novel nucleoside analogs, such as 3-(&bgr;-D-Ribofuranosyl)-2-fluoropyridine, 3-(&bgr;-D-Ribofuranosyl)-pyridin-2-one, 3-(&bgr;-D-Ribofuranosyl)-pyridin-2-(4-nitrophenylethyl)-one, 3-(&agr;-D-Ribofuranosyl)-2-fluoropyridine, 5-(&bgr;-D-Ribofuranosyl)-2-bromopyridine, 5-(&agr;-D-Ribofuranosyl)-2-bromopyridine, 5-(&bgr;-D-Ribofuranosyl)-pyridin-2-one, 5-(&agr;-D-Ribofuranosyl)-pyridin-2-one, 5-(&bgr;-D-Ribofuranosyl)-2-aminopyridine, 5-(&bgr;-D-Ribofuranosyl)-pyridin-2-(4-nitrophenylethyl)-one, and 5-(&agr;-D-Ribofuranosyl)-2-aminopyridine; process for their synthesis and incorporation into polynucleotides.
新型核苷类似物,例如3-(&bgr;-D-核糖呋喃基)-2-氟吡啶,3-(&bgr;-D-核糖呋喃基)-吡啶-2-酮,3-(&bgr;-D-核糖呋喃基)-吡啶-2-(4-硝基苯乙基)-酮,3-(&agr;-D-核糖呋喃基)-2-氟吡啶,5-(&bgr;-D-核糖呋喃基)-2-溴吡啶,5-(&agr;-D-核糖呋喃基)-2-溴吡啶,5-(&bgr;-D-核糖呋喃基)-吡啶-2-酮,5-(&agr;-D-核糖呋喃基)-吡啶-2-酮,5-(&bgr;-D-核糖呋喃基)-2-氨基吡啶,5-(&bgr;-D-核糖呋喃基)-吡啶-2-(4-硝基苯乙基)-酮和5-(&agr;-D-核糖呋喃基)-2-氨基吡啶;它们的合成过程以及它们被纳入多核苷酸的过程。